Grandfield & Dodd, LLC Seagen Inc. Transaction History

Grandfield & Dodd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	SELL	$191.51 - $216.16 $45,004 - $50,797	-235 Reduced 1.53%	15,113 $3.21 Million
Q2 2023 Aug 07, 2023	SELL	$187.64 - $206.25 $10,320 - $11,343	-55 Reduced 0.36%	15,348 $2.95 Million
Q1 2023 Apr 28, 2023	BUY	$127.59 - $203.08 $32,790 - $52,191	257 Added 1.7%	15,403 $3.12 Million
Q4 2022 Jan 20, 2023	BUY	$117.37 - $139.17 $46,243 - $54,832	394 Added 2.67%	15,146 $0
Q3 2022 Nov 03, 2022	BUY	$135.27 - $180.11 $6,763 - $9,005	50 Added 0.34%	14,752 $2.02 Million

Q2 2022 Aug 01, 2022	SELL	$108.81 - $179.33 $761 - $1,255	-7 Reduced 0.05%	14,702 $2.6 Million
Q1 2022 Apr 19, 2022	BUY	$119.61 - $157.85 $32,175 - $42,461	269 Added 1.86%	14,709 $2.12 Million
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $60,734 - $81,306	426 Added 3.04%	14,440 $2.23 Million
Q3 2021 Oct 28, 2021	SELL	$142.45 - $169.82 $113,247 - $135,006	-795 Reduced 5.37%	14,014 $2.38 Million
Q2 2021 Jul 28, 2021	BUY	$135.08 - $161.1 $2,026 - $2,416	15 Added 0.1%	14,809 $2.34 Million
Q1 2021 Apr 22, 2021	BUY	$137.51 - $190.8 $9,350 - $12,974	68 Added 0.46%	14,794 $2.05 Million
Q4 2020 Jan 29, 2021	BUY	$164.63 - $211.93 $2.42 Million - $3.12 Million	14,726 New	14,726 $2.58 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

Stay updated on Grandfield & Dodd, LLC with notifications on news.